13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D Filed 2026-08-11 Event 2026-08-04 SEC 0001178913-26-004023 →

RECANATI LEON Evogene Ltd. EVGN

Stake: 5.70% Shares: 894,836 CUSIP: M4119S187 Class: Ordinary shares, par value NIS 0.20 per share

Item 4 — Purpose of Transaction

The Reporting Person acquired the Ordinary Shares reported herein for investment purposes. The Reporting Person believes that the Ordinary Shares represent an attractive investment opportunity at current market prices and believes in the long-term business prospects of the Issuer. The Reporting Person serves as a member of the board of directors of the Issuer. In connection with the Issuer's 2026 annual general meeting of shareholders, scheduled for September 4, 2026 (the "AGM"), at which there will be a contested director election, the Reporting Person intends to vote all Ordinary Shares beneficially owned by him in favor of the slate of director nominees nominated by the Issuer's current board of directors, and to disregard the slate of directors nominated by the dissident shareholders. The Reporting Person believes that the current board is executing a clear strategic plan that is delivering measurable results, has proactively evolved as the Issuer has transformed, and has demonstrated strong capital allocation and financial discipline. On the other hand, the slate proposed by the dissident shareholders has not presented a comprehensive strategic alternative, despite having been given an opportunity by the current board to do so, and would furthermore create unacceptable disruption risk to the Issuer's current strategic plan, which has been producing positive results. The Reporting Person may, from time to time and depending upon prevailing market conditions, the financial condition, business and prospects of the Issuer, and such other factors as the Reporting Person deems relevant, acquire additional Ordinary Shares or other securities of the Issuer in the open market or in privately negotiated transactions, or dispose of any Ordinary Shares or other securities of the Issuer that the Reporting Person beneficially owns. Except as described herein, the Reporting Person does not currently have any plans or proposals that relate to or would result in any of the transactions or other matters specified in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Person reserves the right to change his plans or intentions at any time, as he deems appropriate in light of the circumstances then prevailing.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
5 13D/G filings on this issuer
4 other filings besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest · settle 2026-07-31
DTC 1.00
45,127 shares short · -81.9% vs prior

Other 13D/G Filings on Evogene Ltd.

FiledFormFilerStakeShares
2026-08-07 SCHEDULE 13D/A L.I.A. Pure Capital Ltd 15.98% 2,524,400 view →
2026-07-27 SCHEDULE 13D/A L.I.A. Pure Capital Ltd 17.41% 2,308,100 view →
2026-07-20 SCHEDULE 13D/A L.I.A. Pure Capital Ltd 2,228,100 view →
2026-07-10 SCHEDULE 13D L.I.A. Pure Capital Ltd 12.61% 1,526,100 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →